var data={"title":"Lidocaine and prilocaine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lidocaine and prilocaine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6464?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lidocaine-and-prilocaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lidocaine and prilocaine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=lidocaine-and-prilocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lidocaine and prilocaine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188755\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AgonEaze;</li>\n      <li>Anodyne LPT;</li>\n      <li>DermacinRx Empricaine;</li>\n      <li>DermacinRx Prizopak;</li>\n      <li>Dolotranz;</li>\n      <li>EMLA [DSC];</li>\n      <li>Leva Set;</li>\n      <li>Lido BDK;</li>\n      <li>Lidopril;</li>\n      <li>Lidopril XR;</li>\n      <li>LiProZonePak;</li>\n      <li>Livixil Pak;</li>\n      <li>LP Lite Pak;</li>\n      <li>Medolor Pak;</li>\n      <li>Oraqix;</li>\n      <li>Prikaan;</li>\n      <li>Prikaan Lite;</li>\n      <li>Prilolid;</li>\n      <li>Priloxx LP;</li>\n      <li>Relador Pak;</li>\n      <li>Venipuncture CPI</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188756\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>EMLA;</li>\n      <li>Oraqix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188773\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Local Anesthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188758\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Anesthetic:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cream (intact skin): <b>Note:</b> Apply a thick layer to intact skin and cover with an occlusive dressing. Dermal analgesia can be expected to increase for up to 3 hours under occlusive dressing and persist for 1 to 2 hours after removal of the cream.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>US labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Minor dermal procedures (eg, IV cannulation or venipuncture):</i> Apply 2.5 g (<sup>1</sup>/<sub>2</sub> of the 5 g tube) over 20 to 25 cm<sup>2</sup> of skin surface area) for at least 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Major dermal procedures (eg, more painful dermatological procedures involving a larger skin area such as split thickness skin graft harvesting):</i> Apply 2 g per 10 cm<sup>2</sup> of skin and allow to remain in contact with the skin for at least 2 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Adult male genital skin (eg, pretreatment prior to local anesthetic infiltration):</i> Apply 1 g per 10 cm<sup>2</sup> to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of cream.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Adult female genital mucous membranes: </i>Minor procedures (eg, removal of condylomata acuminata, pretreatment for local anesthetic infiltration): Apply 5 to 10 g for 5 to 10 minutes. The local anesthetic infiltration or procedure should be performed immediately after removal of cream.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Minor dermal procedures (eg, IV cannulation, venipuncture, surgical or laser treatment):</i> Apply 2 g (~<sup>1</sup>/<sub>2</sub> of the 5 g tube) over ~13.5 cm<sup>2</sup> for at least 1 hour but no longer than 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Major dermal procedures (eg, split-skin grafting):</i> 1.5 to 2 g per 10 cm<sup>2</sup> (maximum: 60 g per 400 cm<sup>2</sup>) for at least 2 hours but no longer than 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Genital mucosa (eg, surgical procedures &le;10 minutes such as localized wart removal, and prior to local anesthetic infiltration):</i> Apply 2 g (~<sup>1</sup>/<sub>2</sub> of 5 g tube) per lesion (maximum: 10 g) for 5 to 10 minutes. Initiate procedure immediately after removing cream.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Leg ulcers (eg, mechanical cleansing/surgical debridement):</i> Apply ~1 to 2 g per 10 cm<sup>2 </sup>(maximum: 10 g) for at least 30 minutes and up to 60 minutes for necrotic tissue that is more difficult to penetrate. Initiate procedure immediately after removing cream.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Periodontal gel (Oraqix): Apply on gingival margin around selected teeth using the blunt-tipped applicator included in package. Wait 30 seconds, then fill the periodontal pockets using the blunt-tipped applicator until gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment. May reapply; maximum recommended dose: One treatment session: 5 cartridges (8.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Transdermal patch [Canadian product]: Minor procedures (eg, needle insertion): Apply 1 or more patches to intact skin surface area &lt;10 cm<sup>2</sup> for at least 1 hour (maximum application time: 5 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188767\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=lidocaine-and-prilocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Lidocaine and prilocaine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Although the incidence of systemic adverse effects is very low, caution should be exercised, particularly when applying over large areas and leaving on for &gt;2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Local anesthetic (procedures):</b> Infants and Children (intact skin): Topical: <b>Note:</b> If a patient &gt;3 months of age does not meet the minimum weight requirement, the maximum total dose should be restricted to the corresponding maximum based on patient weight.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cream: Should <b>not</b> be used in neonates with a gestation age &lt;37 weeks nor in infants &lt;12 months of age who are receiving treatment with methemoglobin-inducing agents</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dosing is based on child's age and weight:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 0 to 3 months or &lt;5 kg: Apply a maximum of 1 g over no more than 10 cm<sup>2</sup> of skin; leave on for no longer than 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 3 months to 12 months and &gt;5 kg: Apply no more than a maximum 2 g total over no more than 20 cm<sup>2</sup> of skin; leave on for no longer than 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 1 to 6 years and &gt;10 kg: Apply no more than a maximum of 10 g total over no more than 100 cm<sup>2</sup> of skin. US labeling recommends leaving on for no longer than 4 hours. Canadian labeling recommends leaving on for no longer than 5 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 7 to 12 years and &gt;20 kg: Apply no more than a maximum 20 g total over no more than 200 cm<sup>2</sup> of skin. US labeling recommends leaving on for no longer than 4 hours. Canadian labeling recommends leaving on for no longer than 5 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Transdermal patch [Canadian product]: <b>Note:</b> Should not be used in neonates with a gestation age &lt;37 weeks nor in infants &lt;12 months of age who are receiving treatment with methemoglobin-inducing agents</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dosing is based on child's age and weight: Apply patch(es) to skin area(s) &lt;10 cm<sup>2</sup></i>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 0 to 3 months or &lt;5 kg: Apply 1 patch and leave on for ~1 hour (do not exceed 1-hour application time); do not apply more than 1 patch at same time; safety of repeated dosing not established</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 3 months to 12 months and &gt;5 kg: Apply 1 to 2 patches for ~1 hour (maximum application time: 4 hours); do not apply more than 2 patches at the same time</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 1 to 6 years and &gt;10 kg: Apply 1 or more patches for minimum of 1 hour (maximum application time: 5 hours); maximum dose: 10 patches</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Age 7 to 12 years and &gt;20 kg: Apply 1 or more patches for a minimum of 1 hour (maximum application time: 5 hours); maximum dose: 20 patches</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188759\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Smaller areas of treatment may be necessary depending on status of patient (eg, debilitated, impaired hepatic function). Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188760\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer labeling. Lidocaine and prilocaine primarily undergo hepatic metabolism and their pharmacokinetics are not expected to be changed significantly in renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188761\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Smaller areas of treatment are recommended for patients with severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AgonEaze: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anodyne LPT: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DermacinRx Empricaine: Lidocaine 2.5% and prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DermacinRx Prizopak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dolotranz: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with lidocaine gel 4%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">EMLA: Lidocaine 2.5% and prilocaine 2.5% (5 g [DSC], 30 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Leva Set: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lido BDK: Lidocaine 2.5% and prilocaine 2.5% (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lidopril: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lidopril XR: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LiProZonePak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Livixil Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LP Lite Pak: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Medolor Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prikaan: Lidocaine 2.5% and Prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prikaan Lite: Lidocaine 2.5% and Prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prilolid: Lidocaine 2.5% and prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Priloxx LP: Lidocaine 2.5% and prilocaine 2.5%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relador Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Venipuncture CPI: Lidocaine 2.5% and prilocaine 2.5% (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Lidocaine 2.5% and prilocaine 2.5% (5 g, 30 g, 5800 g, 18,000 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, periodontal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oraqix: Lidocaine 2.5% and prilocaine 2.5% (1.7 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188725\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Cream</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10193334\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, transdermal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">EMLA Patch: Lidocaine 2.5% and prilocaine 2.5% per patch (2s, 20s) [active contact surface area of each 1 g patch: 10 cm<sup>2</sup>; surface area of entire patch: 40 cm<sup>2</sup>]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188740\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: For external use only. Avoid application to open wounds or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible. In small infants and children, observe patient to prevent accidental ingestion of cream or dressing. To obtain 1 g of cream, squeeze narrow strip ~1.5 inches long and 0.2 inches wide from tube. Repeat as necessary to obtain quantity needed for dose (eg, 2 strips = 2 g dose). Apply a thick layer of cream to designated site of intact skin. Cover site with occlusive dressing. Mark the time on the dressing. Allow at least 1 hour (mild dermatologic procedures) or at least 2 hours (major dermal procedures) for optimum therapeutic effect. Remove the dressing and wipe off excess cream (gloves should be worn). Smaller areas of treatment are recommended for small children, debilitated patients, or patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch [Canadian product]: Apply patch or patches to intact skin. Allow at least 1 hour for optimum therapeutic effect. After removing patch or patches, clean treated areas thoroughly prior to procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oraqix is a viscous liquid. Make sure it is in the liquid form before administration; if semisolid gel forms, refrigerate until becomes liquid again (do not freeze). Do not use dental cartridge warmers; heat will cause product to gel prematurely (product is a microemulsion which is intended to form a gel in the periodental pocket). Apply slowly and evenly on gingival margin around selected teeth using the provided blunt-tipped applicator. Wait 30 seconds, then fill the periodontal pockets using the blunt-tipped applicator until gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188739\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream: Topical anesthetic for use on normal intact skin to provide local analgesia; for use on genital mucous membranes for superficial minor surgery; and as pretreatment for infiltration anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Periodontal gel: Topical anesthetic for use in periodontal pockets during scaling and/or root planing procedures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream: Topical anesthetic for use on intact skin in connection with: IV cannulation or venipuncture; superficial surgical procedures (eg, split skin grafting, electrolysis, removal of molluscum contagiosum); laser treatment for superficial skin surgery (eg, telangiectasia, port wine stains, warts, moles, skin nodules, scar tissue); surgical procedures of genital mucosa (&le;10 minutes) on small superficial localized lesions (eg, removal of condylomata by laser or cautery, biopsies); local infiltration anesthesia in genital mucous membranes; mechanical cleansing/debridement of leg ulcers; vaccination with measles-mumps-rubella (MMR), diphtheria-pertussis-tetanus-poliovirus (DPTP), <i>Haemophilus influenzae</i> b, and hepatitis B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patch: Topical anesthetic for use on intact skin in connection with IV cannulation or venipuncture; vaccination with measles-mumps-rubella (MMR), diphtheria-pertussis-tetanus-poliovirus (DPTP), <i>Haemophilus influenzae</i> b, and hepatitis B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Periodontal gel: Topical anesthetic for use in periodontal pockets during scaling and/or root planing procedures </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188732\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cream/patch:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pallor (local: 37%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema (21% to 30%), application site burning (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Local alterations in temperature sensations (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site edema (6% to 10%), application site pruritus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperpigmentation, stinging of the skin (local), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Local purpuric or petechial reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, angioedema, application site rash, blistering of foreskin, bronchospasm, central nervous system depression, central nervous system stimulation, central nervous system toxicity (high dose), circulatory shock (high dose), hypotension, local hypersensitivity reaction, methemoglobinemia (high dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodontal gel:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Application site reaction (13%, includes abscess, edema, irritation, numbness, pain, ulceration, vesicles)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Bitter taste (2%), fatigue (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Local hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (1%), respiratory tract infection (1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188743\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to local anesthetics of the amide type or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Congenital or idiopathic methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cream and patch only: Infants &le;12 months of age who require treatment with methemoglobin-inducing agents; preterm infants (gestational age &lt;37 weeks); procedures requiring large amounts over a large body area that are not conducted in a facility with health care professionals trained in the diagnosis and management of dose-related toxicity and other acute emergencies, and with appropriate resuscitative treatments and equipment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188729\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Allergic and anaphylactic reactions may occur. Patients allergic to paraaminobenzoic acid derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine and/or prilocaine; use with caution in patients with a history of drug sensitivities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: Has been reported in infants and children; associated with large doses, larger-than-recommended areas of application, neonates and infants &lt;3 months of age, and concomitant use of methemoglobinemia-inducing agents (eg, acetaminophen, benzocaine, chloroquine, dapsone, nitrofurantoin, nitroglycerin, nitroprusside, phenobarbital, phenytoin, quinine, sulfonamides). Neonates and infants up to 3 months of age should be monitored for methemoglobinemia. Do not use in preterm neonates (gestational age &lt;37 weeks), infants &lt;12 months of age requiring treatment with methemoglobinemia-inducing agents, or in patients with congenital or idiopathic methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Atopic dermatitis: Use with caution; rapid and greater absorption through the skin is observed in these patients; a shorter application time should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with severe impairment of impulse initiation and conduction in the heart (eg, grade II and III AV block, pronounced bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD may be more susceptible to drug-induced methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; risk of increased systemic exposure. Smaller treatment area may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill; smaller treatment area may be required consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patients; smaller treatment area may be required consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in elderly patients; smaller treatment area may be required consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Periodontal gel: Do not use with standard dental syringes; only use with the supplied blunt-tipped applicator.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Although the incidence of systemic adverse reactions with use of the cream is very low, caution should be exercised, particularly when applying over large areas and leaving on for longer than 2 hours. When used prior to cosmetic or medical procedures, the smallest amount of cream necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heartbeats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for a prolonged time, or have used wraps/dressings to cover the skin following application. Do not apply to broken or inflamed skin, open wounds, or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible; ototoxicity has been observed in animal studies. Avoid inadvertent trauma to the treated area (eg, scratching, rubbing, exposure to extreme hot or cold temperatures) until complete sensation has returned.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188768\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188733\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9561&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188735\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188746\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination. Lidocaine and prilocaine cross the placenta. Their use is not contraindicated during labor and delivery. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188747\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Lidocaine is excreted in breast milk; excretion of prilocaine in breast milk unknown; however, systemic absorption following topical application is expected to be low. The manufacturer recommends that caution be exercised when administering to nursing women. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20421842\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum methemoglobin before, during, and after use in neonates and infants up to 3 months of age. Consider ECG monitoring in patients treated with Class III antiarrhythmic drugs (eg, amiodarone).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188728\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Local anesthetic action occurs by stabilization of neuronal membranes and inhibiting the ionic fluxes required for the initiation and conduction of impulses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188742\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">EMLA: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onset of action: 1 hour (more rapid in genital mucosa: 5 to 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peak effect: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duration: 1 to 2 hours after removal; Genital mucosa: 15 to 20 minutes after application (range: 5 to 45 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorption: Related to duration of application and area where applied </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">3-hour application: 3.6% lidocaine and 6.1% prilocaine </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">24-hour application: 16.2% lidocaine and 33.5% prilocaine </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oraqix:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onset of action: &le;30 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duration: ~20 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188745\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidocaine-Prilocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (5 g): $8.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (CadiraMD External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $259.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (DermacinRx Empricaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,479.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (DermacinRx Prizopak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,801.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Dolotranz External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5 &amp; 4% (1): $2,145.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Leva Set/Occlusive Dressing External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,200.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lido BDK External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $249.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lido-Prilo Caine Pack External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,885.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lidocaine-Prilocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $49.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LiProZonePak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,987.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Livixil Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,660.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LP Lite Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $438.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Medolor Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,771.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Prikaan External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,498.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Prikaan Lite External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $494.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Priloxx LP External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,986.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Relador Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,651.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Relador Pak Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,675.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Venipuncture CPI External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $828.28</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188748\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anesteal (ES);</li>\n      <li>Anestecin crema (CO);</li>\n      <li>Anestesin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Anestil (EC);</li>\n      <li>Ansederm (FR);</li>\n      <li>Cainplus (LK);</li>\n      <li>Denela (ES, MT);</li>\n      <li>Dermacaine (TH);</li>\n      <li>Dolones (ID);</li>\n      <li>Duocaine (MY);</li>\n      <li>Emla (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CY, CZ, DE, DK, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, ID, IE, IL, IQ, IR, IS, IT, JM, JO, JP, KE, KW, LB, LK, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PL, PY, QA, RU, SA, SC, SD, SE, SI, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>EMLA (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Emla Cream (NZ);</li>\n      <li>Emla Patch (NZ);</li>\n      <li>Emlocaine (PH);</li>\n      <li>Encain (HK);</li>\n      <li>Fortacin (IE);</li>\n      <li>Lidiprine (HK);</li>\n      <li>Liprido (TW);</li>\n      <li>Liprikaine (TH);</li>\n      <li>Lipril Cream (KR);</li>\n      <li>Lipro (MY);</li>\n      <li>Metacain DS (PH);</li>\n      <li>Oraqix (IE, SE);</li>\n      <li>Prila (QA);</li>\n      <li>Prilox (IN);</li>\n      <li>Racser (MY);</li>\n      <li>Skisia (BD);</li>\n      <li>Topsy (ID);</li>\n      <li>Xylocream (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Broadman LM, Soliman IE, Hannallah RS, et al, &ldquo;Analgesic Efficacy of Eutectic Mixture of Local Anesthetics (EMLA) Vs Intradermal Infiltration Prior to Venous Cannulation in Children,&rdquo; <i>Am J Anaesthesiol</i>, 1987, 34:S56.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EMLA (lidocaine and prilocaine) [prescribing information]. Parsippany, NJ: Actavis Pharma; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EMLA (lidocaine and prilocaine) [product monograph]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friskopp J and Huledal G, &ldquo;Plasma Levels of Lidocaine and Prilocaine After Application of Oraqix, a New Intrapocket Anesthetic, in Patients With Advanced Periodontitis,&rdquo; <i>J Clin Periodontol</i>, 2001, 28(5):425-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/11350505 /pubmed\" target=\"_blank\" id=\"11350505 \">11350505 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friskopp J, Nilsson M, and Isacsson G, &ldquo;The Anesthetic Onset and Duration of a New Lidocaine/Prilocaine Gel Intra-Pocket Anesthetic (Oraqix) for Periodontal Scaling/Root Planing,&rdquo; <i>J Clin Periodontol</i>, 2001, 28(5):453-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/11350509 /pubmed\" target=\"_blank\" id=\"11350509 \">11350509 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin DL, Koren G, Attias D, et al, &ldquo;Topical Skin Anesthesia for Venous Subcutaneous Drug Reservoir and Lumbar Puncture in Children,&rdquo; <i>Pediatrics</i>, 1989, 84(2):281-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/2748256/pubmed\" target=\"_blank\" id=\"2748256\">2748256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oraqix (lidocaine and prilocaine) [prescribing information]. York, PA: Dentsply Corporate; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oraqix (lidocaine and prilocaine) [product monograph]. Woodbridge, Ontario, Canada: Dentsply Canada Limited; April 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robieux I, Kumar R, Radhakrishnan S, et al, &ldquo;Assessing Pain and Analgesia With a Lidocaine-Prilocaine Emulsion in Infants and Toddlers During Venipuncture,&rdquo; <i>J Pediatr</i>, 1991, 118(6):971-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/2040936/pubmed\" target=\"_blank\" id=\"2040936\">2040936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taddio A, Shennan AT, Stevens B, et al, &ldquo;Safety of Lidocaine-Prilocaine Cream in the Treatment of Preterm Neonates,&rdquo; <i>J Pediatr</i>, 1995, 127(6):1002-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/8523173/pubmed\" target=\"_blank\" id=\"8523173\">8523173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vickers ER, Mazbani N, Gerzina TM, et al, &ldquo;Pharmacokinetics of EMLA Cream 5% Application to Oral Mucosa,&rdquo; <i>Anesth Prog</i>, 1997, 44:32-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/9481979/pubmed\" target=\"_blank\" id=\"9481979\">9481979</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9561 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F188755\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F188756\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F188773\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F188758\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F188767\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F188759\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F188760\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F188761\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F188738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F188725\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10193334\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F188740\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F188739\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F188732\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F188743\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F188729\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F188768\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F188733\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F188735\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F188746\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F188747\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20421842\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F188728\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F188742\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F188745\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F188748\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9561|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lidocaine-and-prilocaine-patient-drug-information\" class=\"drug drug_patient\">Lidocaine and prilocaine: Patient drug information</a></li><li><a href=\"topic.htm?path=lidocaine-and-prilocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine and prilocaine: Pediatric drug information</a></li></ul></div></div>","javascript":null}